Allarity Therapeutics reports Q2 2026 results; Stenoparib Phase 3-ready campaign completed
Allarity Therapeutics reports second quarter 2026 results and states it has completed the Phase 3-ready Stenoparib manufacturing campaign.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.